GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability

(2011) A. J. Garber   DIABETES CARE

Management of type 2 diabetes: new and future developments in treatment

(2011) Abd A Tahrani et al.   LANCET

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

(2011) Gianluca Svegliati-Baroni et al.   LIVER INTERNATIONAL

Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes

(2011) Padma Sathyanarayana et al.   Obesity

Nonalcoholic Fatty Liver Disease: A Review and Update

(2010) Jeffrey R. Lewis et al.   DIGESTIVE DISEASES AND SCIENCES

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

GLP-1 (9–36) Amide Metabolite Suppression of Glucose Production in Isolated Mouse Hepatocytes

(2010) E. Tomas et al.   HORMONE AND METABOLIC RESEARCH

Naringenin Prevents Dyslipidemia, Apolipoprotein B Overproduction, and Hyperinsulinemia in LDL Receptor-Null Mice With Diet-Induced Insulin Resistance

(2009) E. E. Mulvihill et al.   DIABETES

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

(2009) J. Hsieh et al.   DIABETOLOGIA

Direct Control of Peripheral Lipid Deposition by CNS GLP-1 Receptor Signaling Is Mediated by the Sympathetic Nervous System and Blunted in Diet-Induced Obesity

(2009) R. Nogueiras et al.   JOURNAL OF NEUROSCIENCE

Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor-Dependent Control of Glucose Homeostasis

(2008) K. M. Picha et al.   DIABETES

CNTO736, a Novel Glucagon-Like Peptide-1 Receptor Agonist, Ameliorates Insulin Resistance and Inhibits Very Low-Density Lipoprotein Production in High-Fat-Fed Mice

(2008) E. T. Parlevliet et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS